Therapeutic Drug Monitoring for Sirolimus in Children with Vascular Anomalies: What Can We Learn from a Retrospective Study

被引:0
作者
Hu, Ya-Hui [1 ]
Zhao, Yue-Tao [1 ,2 ]
Guo, Hong-Li [1 ]
Li, Yue [1 ]
Zhang, Yuan-Yuan [1 ]
Wang, Jie [1 ]
Ding, Xuan-Sheng [2 ]
Zou, Ji-Jun [3 ]
Chen, Feng [1 ]
机构
[1] Nanjing Med Univ, Pharmaceut Sci Res Ctr, Dept Pharm, Childrens Hosp, Nanjing 210008, Peoples R China
[2] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing 210009, Peoples R China
[3] Nanjing Med Univ, Dept Burns & Plast Surg, Childrens Hosp, Nanjing 210008, Peoples R China
关键词
sirolimus; vascular anomalies; children; therapeutic drug monitoring; <italic>C</italic>trough/Dose ratio; MAMMALIAN TARGET; RAPAMYCIN; MTOR; EFFICACY; GROWTH; SAFETY;
D O I
10.3390/ph17101255
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objectives: Sirolimus (SRL), a mammalian target of rapamycin inhibitor, has been widely used to treat patients with vascular anomalies (VAs). The objectives of this study were to summarize the routine blood SRL monitoring data for VAs children, to investigate the factors contributing to the variable blood SRL concentrations and to evaluate the efficacy and safety of SRL therapy. Methods: VAs patients with routine blood SRL monitoring from July 2017 to April 2022 at the Department of Burns and Plastic Surgery, Children's Hospital of Nanjing Medical University were retrospectively collected. Clinical data were obtained from the hospital information system. Results: In total, 67 children (35 females) were enrolled. The therapeutic drug monitoring data showed that the range of measured blood trough concentrations (Ctrough) was 3.6-46.8 ng/mL. At the initial measurements, only 33% of patients were in the target concentration range (10-15 ng/mL). But this proportion became 54% at the last measurements. The whole blood-Ctrough-to-daily dose (Ctrough/Dose) ratio was significantly associated with age and body weight (BW). The patients' laboratory results did not change significantly after SRL treatment. Although the incidence of adverse events was relatively high (44.8%), most of them were mild and tolerable. 70.3% patients had total responses to SRL, whereas 29.7% children exhibited stable disease or progressive disease. No significant differences were found in Ctrough between the total response group and non-response group. Conclusions: This retrospective study revealed a high variability in SRL blood concentrations in Chinese children with VAs. Of note, pediatric patients with older age and a higher BW had a lower Ctrough/Dose ratio. It is a concern whether the range of 10-15 ng/mL is feasible for Chinese children based only on our study. Further studies recruiting more patients are required to redefine the target reference range for children with VAs.
引用
收藏
页数:15
相关论文
共 41 条
  • [1] Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
    Adams, Denise M.
    Trenor, Cameron C., III
    Hammill, Adrienne M.
    Vinks, Alexander A.
    Patel, Manish N.
    Chaudry, Gulraiz
    Wentzel, Mary Sue
    Mobberley-Schuman, Paula S.
    Campbell, Lisa M.
    Brookbank, Christine
    Gupta, Anita
    Chute, Carol
    Eile, Jennifer
    McKenna, Jesse
    Merrow, Arnold C.
    Fei, Lin
    Hornung, Lindsey
    Seid, Michael
    Dasgupta, A. Roshni
    Dickie, Belinda H.
    Elluru, Ravindhra G.
    Lucky, Anne W.
    Weiss, Brian
    Azizkhan, Richard G.
    [J]. PEDIATRICS, 2016, 137 (02)
  • [2] Pediatric reference intervals for 32 routine biochemical markers using the siemens healthineers atellica® CH assays in healthy children and adolescents
    Bohn, Mary Kathryn
    Horn, Paul
    League, Donna
    Steele, Paul
    Hall, Alexandra
    Adeli, Khosrow
    [J]. CLINICAL BIOCHEMISTRY, 2022, 99 : 69 - 77
  • [3] Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability
    Burke, Jacqueline A.
    Zhang, Xiaomin
    Bobbala, Sharan
    Frey, Molly A.
    Fuentes, Carolina Bohorquez
    Haddad, Helena Freire
    Allen, Sean D.
    Richardson, Reese A. K.
    Ameer, Guillermo A.
    Scott, Evan A.
    [J]. NATURE NANOTECHNOLOGY, 2022, 17 (03) : 319 - +
  • [4] The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia
    Cheng, Xiaoling
    Zhao, Yiming
    Gu, Hao
    Zhao, Libo
    Zang, Yannan
    Wang, Xiaoling
    Wu, Runhui
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2020, 34
  • [5] Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review
    Freixo, Cristiana
    Ferreira, Vitor
    Martins, Joana
    Almeida, Rui
    Caldeira, Daniel
    Rosa, Mario
    Costa, Joao
    Ferreira, Joaquim
    [J]. JOURNAL OF VASCULAR SURGERY, 2020, 71 (01) : 318 - 327
  • [6] Growth of kidney-transplanted pediatric patients treated with sirolimus
    Gonzalez, David
    Garcia, Clotilde D.
    Azocar, Marta
    Waller, Simon
    Alonso, Angel
    Ariceta, Gema
    Mejia, Natalia
    Santos, Fernando
    [J]. PEDIATRIC NEPHROLOGY, 2011, 26 (06) : 961 - 966
  • [7] Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis
    Huber, S.
    Bruns, C. J.
    Schmid, G.
    Hermann, P. C.
    Conrad, C.
    Niess, H.
    Huss, R.
    Graeb, C.
    Jauch, K-W
    Heeschen, C.
    Guba, M.
    [J]. KIDNEY INTERNATIONAL, 2007, 71 (08) : 771 - 777
  • [8] ISSVA, 2018, Classification of Vascular Anomalies
  • [9] Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial
    Ji, Yi
    Chen, Siyuan
    Zhou, Jiangyuan
    Yang, Kaiying
    Zhang, Xuepeng
    Xiang, Bo
    Qiu, Tong
    Gong, Xue
    Zhang, Zixin
    Lan, Yuru
    Hu, Fan
    Kong, Feiteng
    Qiu, Qingxia
    Zhang, Yongbo
    [J]. BLOOD, 2022, 139 (11) : 1619 - 1630
  • [10] A prospective multicenter study of sirolimus for complicated vascular anomalies
    Ji, Yi
    Chen, Siyuan
    Yang, Kaiying
    Zhou, Jiangyuan
    Zhang, Xuepeng
    Jiang, Xian
    Xu, Xuewen
    Lu, Guoyan
    Qiu, Liqing
    Kong, Feiteng
    Zhang, Yongbo
    [J]. JOURNAL OF VASCULAR SURGERY, 2021, 74 (05) : 1673 - +